In this retrospective single centre study we have focused the analysis only in the subgroup of MPO vasculitis with severe renal involvement, because of scarce data in the use of RTX in these patients and the likely increased effectiveness of RTX in PR3 disease, as reported by some authors [20]. This evidence concerns the gene MPO and vasculitis.